Illimis Therapeutics is a Korean biotech company founded in 2021, with a focus on developing a chimeric fusion protein platform for neurodegenerative diseases, particularly Alzheimer's. The startup differentiates itself through its innovative approach to address the concerns of antibody-induced neuroinflammation and ARIA (Amyloid-Related Imaging Abnormalities). Illimis Therapeutics utilizes TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells, to overcome the limitations observed in existing antibody drugs that utilize FcR-mediated phagocytosis of microglia. This unique platform has attracted attention from the biopharma, biotechnology, health care, and pharmaceutical industries. The startup has received a Venture Round investment on 01 January 2023 from prominent investors including Company K Partners, DAYLI Partners, and STIC. Illimis Therapeutics' cutting-edge technology and its potential to significantly impact the treatment of neurodegenerative diseases make it a compelling opportunity for venture capital firms seeking to invest in groundbreaking biotech solutions. The company's headquarters is located in South Korea, positioning it within a thriving hub for innovation in the biotech and pharmaceutical sectors. Illimis Therapeutics' disruptive approach and strong investment support highlight its potential as a key player in the advancement of treatments for neurodegenerative diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 3 |
|
01 Jan 2023 |
No recent news or press coverage available for Illimis Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.